

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Indicator Equality Impact Assessment

Indicator: IND211

Subject: HIV testing with other blood tests in areas of high or extremely high HIV prevalence

1.1 Have any potential equality issues been identified during the development process?

No.

1.2 Have any population groups, treatments or settings been excluded from coverage by the indicator? Are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

The indicator is targeted at areas with high or extremely high HIV prevalence in order to reduce late diagnosis and transmission of HIV where people are most at risk. People in low prevalence areas can still access HIV testing, however guidance does not recommend testing when having a blood test in these areas.

1.3 Does the indicator make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

1.4 Is there potential for the indicator to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

Completed by lead technical analyst: Eileen Taylor

Date 18/7/19

Approved by NICE quality assurance lead: Craig Grime

Date 23/07/2019

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).